货号：348047

品牌：BD IS

规格：

目录价：￥4520.00

市场价格：￥3164.00

会员价格：￥2938.00

金山科研平台，产品价格货期咨询微信：jinshanbio

Catalog Number

348047

Name

CD28

Size

100Tests

RegulatoryStatus

RUO (GMP)

Clone

L293

Format

PE

Isotype

IgG₁, κ

W.S. No

none

W.B. Positive Control

none

Molecular Weight

none

Reactivity

QC Testing : Human

Applications

Flow cytometry

- Routinely Tested

Clone - Description

The CD28 (Leu™-28) antigen, a disulfide-linked homodimeric glycoprotein (Mr 44 kd), is a cell-adhesion molecule (CAM) and functions as the ligand for CD80 (B7-1) and CD86 (B7-2) antigens, which are present on activated B lymphocytes, monocytes, and dendritic cells. Interaction of the CD28 antigen with CD80 and/or CD86 antigens co-stimulates CD2 and CD3 antigen/T-cell antigen receptor (TCR)–dependent T-cell–mediated proliferation and cytotoxicity.The CD28 antigen is present on approximately 60% to 80% of peripheral blood T (CD3⁺) lymphocytes, 95% of CD4⁺ T lymphocytes, 50% of CD8⁺ T lymphocytes, and 5% of immature CD3^- thymocytes. T lymphocytes that lack the CD28 antigen reciprocally express the CD11b antigen. During thymocyte maturation, CD28 antigen expression increases from a low density on most CD4⁺CD8⁺ immature thymocytes to a higher density on virtually all mature CD3⁺, CD4⁺, or CD8⁺ thymocytes. Cell activation further augments CD28 antigen density. Both CD4⁺ and CD8⁺ T-lymphocyte subsets can be separated into two functionally distinct subsets based on CD28 antigen density. These subsets differ in their cytotoxic and lymphokine-production capabilities. CD4⁺ lymphocytes that express high levels of the CD28 antigen lack CD3-mediated cytotoxic ability and produce only minimal amounts of cytokines while CD4⁺ lymphocytes that express low levels of the CD28 antigen possess CD3-mediated cytotoxic ability and produce interleukin-2 (IL-2), g-interferon (IFN- g), and tumor necrosis factor–a/b (TNF-a/b). Expression of the CD28 antigen also divides the CD8⁺ lymphocyte subset into two functional groups. CD8⁺CD28⁺ lymphocytes tend to have long-term proliferative capacity in vitro and in vivo, while CD8⁺CD28^- lymphocytes are thought to be effector cells with limited proliferative capacity.